AGAF

Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference

Retrieved on: 
Thursday, March 28, 2024
Washington Convention Center, Walter, FACG, FACP, AGAF, University, IGG, DDW, Gastroenterology, IBS, RFF

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Session at the 2024 Digestive Disease Week (DDW) Annual Meeting in Washington DC.

Key Points: 
  • IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Session at the 2024 Digestive Disease Week (DDW) Annual Meeting in Washington DC.
  • DDW is renowned as the world's premier scientific and clinical meeting for digestive disease health care professionals.
  • "We are excited that our technology will be prominently featured in a presentation at this year's DDW conference," said CEO Zack Irani.
  • "The forthcoming presentation marks a significant milestone, contributing valuable data to the growing clinical evidence supporting the efficacy of the InFoods IBS technology."

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis

Retrieved on: 
Thursday, February 15, 2024
Diabetes, Obesity, Cancer, CK Life Sciences, Goel, Risk, CK Hutchison Holdings, MicroRNA, Biomarker, History, Therapy, PDAC, Tobacco, Patient, Pancreas, Disease, Diagnosis, Machine learning, AGAF, Molecular diagnostics, Pancreatic cancer, Mortality, Abdominal cavity, Research, Insurance, Medical imaging

LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC).

Key Points: 
  • LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC).
  • This license agreement marks a pivotal step with PharusDx to develop and commercialize a version of its OncoSweep™ liquid biopsy screening for the early detection of PDAC.
  • The poor survival rate is mainly due to late-stage diagnosis, attributed to the pancreas' deep location within the abdominal cavity.
  • The current challenge of asymptomatic early diagnosis of PDAC is anticipated to be addressed by PharusDx's liquid biopsy miRNA test: OncoSweep™.

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Retrieved on: 
Sunday, February 4, 2024
ALP, AGAF, IBD, Ascending cholangitis, Liver failure, Pharmacokinetics, SAN, Washington State University, Inflammation, Fibrosis, Cirrhosis, Itch, PSC, Ursodeoxycholic acid, MRI, Telephone, Magnetic resonance imaging, Inflammatory bowel disease, Patient, Safety, FDA, EMA, FACP, Disease, IPF, SAE, FRCP, ELF, Week, Therapy, Conference call, Alkaline phosphatase, Interest, UDCA, FACG, University, Webcast, Liver, Primary sclerosing cholangitis, Plasma, Liver disease, Conference, Medical imaging

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period and its plasma concentrations increased with dose. There was no dose relationship for adverse events. Pruritus and cholangitis occurred less frequently on bexotegrast than on placebo.

Key Points: 
  • The trial’s exploratory efficacy endpoints assessed changes in the liver fibrosis markers, Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels, as well as liver biochemistry and magnetic resonance imaging (MRI) of the liver.
  • In addition, MRI imaging continued to show evidence of improved hepatocyte function and bile flow with bexotegrast at the 320 mg dose relative to placebo.
  • INTEGRIS-PSC is a multinational, randomized, dose-ranging, double-blind, placebo-controlled Phase 2a trial evaluating bexotegrast at once-daily oral doses of 40 mg, 80 mg, 160 mg, 320 mg or placebo for 12 weeks in 121 patients with PSC.
  • The 320 mg group enrolled 27 patients in the active arm and added 9 new patients to the pooled placebo arm.

Velocity aggressively expands MASH/MASLD capabilities with latest site acquisitions

Retrieved on: 
Wednesday, October 25, 2023
Potsdam Institute for Climate Impact Research, Gastroenterology, FDA, Research, Oregon Health & Science University, United States Department of the Air Force, Obesity, General Social Care Council, Prevalence, Biological therapy for inflammatory bowel disease, Liver disease, Paulinum (University of Leipzig), ChromeOS, CPI, Tufts University School of Medicine, AGAF, Growth, Disease, St George's Hospital, NASH, University, KOL, Internal medicine, Icahn School of Medicine at Mount Sinai, Air force, Brooke Army Medical Center, DURHAM, FACP, FACG, Hepatology, Veteran, Patient, MASH, Dietary supplement, Pharmaceutical industry, Medical device, Nursing, MD, Velocity

DURHAM N.C., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease).

Key Points: 
  • Velocity is a major player in this space with 23 sites capable of performing MASH/MASLD studies globally.
  • With the two recent site acquisitions, Velocity adds two internationally renowned researchers and key opinion leaders (KOL) in liver disease research as principal investigators, Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, and Nadege Gunn, MD, CPI, who join Roland Kuchta, MD, in Germany.
  • Dr. Gunn commented, “We are fully prepared to make Velocity the first-choice site network for liver disease clinical trials worldwide.
  • Velocity has over 80 locations globally and access to more than 220 principal investigators and one million patients.

ACG 2023 Presentations for REBYOTA® (fecal microbiota, live – jslm) Explore Association Between Gut Microbiome Composition and Health-Related Quality of Life and Evaluate Efficacy and Safety in Older Patients With Comorbidities

Retrieved on: 
Monday, October 23, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Clostridioides difficile infection, Yale School of Medicine, PUNCH, GI, Patient, American College, Food, Gammaproteobacteria, ACG, MD, Clostridioides difficile, Atrial fibrillation, Coronary artery disease, Safety, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bacteroidales, Microbiota, Multimedia, Life, Chronic kidney disease, Ferring Pharmaceuticals, AGAF, Recurrence, OLS, Bacteria, Kidney disease, Kidney, Overalls, Irritable bowel syndrome, FACG, Inflammatory bowel disease, Gastroesophageal reflux disease, Pharmaceutical industry, Bacilli

Patients were categorized as improved if Cdiff32 scores improved 10 points or more from baseline to week 8.

Key Points: 
  • Patients were categorized as improved if Cdiff32 scores improved 10 points or more from baseline to week 8.
  • The average microbiome profiles were then compared between baseline and week 8 within the improved and unchanged groups, respectively.
  • The analysis found that the quartile with the highest Cdiff32 score showed a significantly different microbiome composition from most other groups with lower scores.
  • “Seeing efficacy and safety consistent with previous clinical trials of REBYOTA among these higher-risk patients is encouraging.”

United Digestive Physician Achieves 'Best Of' Honor in Savannah Magazine

Retrieved on: 
Thursday, October 5, 2023
UD, MPH, Health, AGAF, FACP, Digestive, Patient, Gastroenterology, Nursing, Savanna, MD

SAVANNAH, Ga., Oct. 5, 2023 /PRNewswire/ -- United Digestive (UD) is pleased to announce that Mark E. Murphy, MD, FACP, AGAF, from Center for Digestive & Liver Health, has been named "Best Gastroenterologist" in Savannah Magazine's "The Best of Savannah Doctors 2023" edition. Dr. Murphy's recognition exemplifies UD's unwavering commitment to delivering best-in-class patient care.

Key Points: 
  • SAVANNAH, Ga., Oct. 5, 2023 /PRNewswire/ -- United Digestive (UD) is pleased to announce that Mark E. Murphy, MD, FACP, AGAF , from Center for Digestive & Liver Health , has been named "Best Gastroenterologist" in Savannah Magazine's "The Best of Savannah Doctors 2023" edition.
  • "We are proud of Dr. Mark Murphy's well-deserved achievement as the 'Best Gastroenterologist' in Savannah," said UD's Chief Medical Officer John Suh, MD, MPH.
  • "I am truly honored to be recognized by Savannah Magazine," said Dr. Murphy.
  • According to Savannah Magazine, "Best of" Savannah Doctors winners were determined by reader votes alone.

AI Medical Service Inc. Signs Joint Research Agreement with US Leading Cancer Institution  

Retrieved on: 
Thursday, August 24, 2023
Technology, Health, Other Health, Professional Services, Artificial Intelligence, Oncology, Other Technology, Research, Medical Devices, Start-Up, Hospitals, Health Technology, Science, Data Management, Memorial Sloan Kettering Cancer Center, School health and nutrition services, Gastrointestinal cancer, Comment, AIM, AGAF, Hepatology, MD, Patient, Physician, MSK, Stomach cancer, Diagnosis, Stomach, Medical device

(hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement with Memorial Sloan Kettering Cancer Center (MSK), one of the world’s top medical research institutes on July 27, 2023.

Key Points: 
  • (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement with Memorial Sloan Kettering Cancer Center (MSK), one of the world’s top medical research institutes on July 27, 2023.
  • AIM is the first Japanese company*1 to sign a joint research agreement with MSK in the field of gastrointestinal endoscopy AI.
  • Its collaboration with MSK will facilitate joint research to investigate the application of Japanese gastrointestinal endoscopy AI in the United States.
  • Comment from CEO of AIM, Dr. Tomohiro Tada
    "I am very pleased that we have established a joint research agreement with Memorial Sloan Kettering Cancer Center (MSK), one of the world’s leading cancer research centers.

American College of Gastroenterology and American Gastroenterological Association Invest in Oshi Health to Accelerate Adoption of Hybrid Digestive Health Care

Retrieved on: 
Tuesday, June 13, 2023
Insurance, University of California, San Diego Performance-Based Skills Assessment, FACG, Partnership, University, Health policy, Diabetes, American Gastroenterological Association, Workplace, Quality of life, Human, MBA, Science, Nature Reviews Gastroenterology & Hepatology, AGAF, AGA, Patient, AHIP, Outline of health sciences, DHPA, System, American College of Gastroenterology, American College, Treasurer, Society, GI, ACG, Nursing, Pharmaceutical industry, Oshi, MD, Gastroenterology

PORTLAND, Ore., June 13, 2023 (GLOBE NEWSWIRE) -- AHIP 2023 CONFERENCE -- Oshi Health today announced strategic investments by the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) GI Opportunity Fund .

Key Points: 
  • PORTLAND, Ore., June 13, 2023 (GLOBE NEWSWIRE) -- AHIP 2023 CONFERENCE -- Oshi Health today announced strategic investments by the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) GI Opportunity Fund .
  • As part of the arrangement, both the ACG and AGA have made strategic financial investments in Oshi Health as an illustration of the importance of providing patients access to the evidence-based, multidisciplinary care offered by Oshi.
  • “As an organization, ACG aims to empower gastroenterologists to embrace the science supporting new guidelines and how to integrate them into clinical practice.
  • Lack of access to multidisciplinary care and support between traditional GI care visits can result in poor patient outcomes and avoidable emergency services.

CELLF BIO Achieves Milestone With First In Human Implantation of BioSphincter™

Retrieved on: 
Tuesday, June 6, 2023
Clinical trial, FI, Cell, Stem cell, Embarrassment, Colon, Fecal incontinence, AGAF, Patient, Social isolation, NIH, Pharmaceutical industry, Doctor of Philosophy

RICHMOND, Va., June 06, 2023 (GLOBE NEWSWIRE) -- CELLF BIO achieved a major milestone with the world's first human implantation of BioSphincter™, an autologous bioengineered sphincter made of smooth muscle and differentiated neural stem cells.

Key Points: 
  • RICHMOND, Va., June 06, 2023 (GLOBE NEWSWIRE) -- CELLF BIO achieved a major milestone with the world's first human implantation of BioSphincter™, an autologous bioengineered sphincter made of smooth muscle and differentiated neural stem cells.
  • The implantation surgery was performed by Dr. Jaime Bohl, chief of colon and rectal surgery at the Virginia Commonwealth University School of Medicine in Richmond, Virginia.
  • "We are very pleased with the progress of the clinical trial thus far," said CELLF BIO CEO Dr. Khalil N. Bitar, PhD, AGAF.
  • CELLF BIO has been selected to present for the NIH booth at the BIO International Convention June 6th, 2023.